Recombinant human interleukin-2 for injection

This product is a lymphokine that can proliferate cytotoxic T cells, natural killer cells and lymphokine-activated killer cells and enhance their killing activity. It can also promote lymphocytes to secrete antibodies and interferons, and has anti-viral, anti-tumor and immune enhancement effects. Long-term toxicity tests on animals have shown that no abnormalities were found in blood picture, blood and urine biochemical tests, circulatory system examinations, and pathological histological examinations.

Main ingredients: recombinant human interleukin-2, human serum albumin.

This product is a white, thin, loose shell, easily soluble in water. After dissolution, it becomes a transparent liquid with no insoluble matter visible to the naked eye.

It is used to treat adult metastatic renal cell carcinoma (RCC) and melanoma and other malignant tumors, and is also suitable for the control of cancerous pleural effusion and ascites.

This product should be used under the guidance of a clinical physician. Dissolve it with sterile water for injection before injection. The specific usage, dosage and course of treatment vary according to the disease. Generally, the following methods are used: 1. Systemic administration: subcutaneous or intramuscular injection: recombinant human interleukin-2.5 to 1 million IU/m2, subcutaneous or intramuscular injection 2 to 3 times/week, 4 to 6 weeks as a course of treatment. 2. Regional and local administration: (1) Thoracic and abdominal cavity injection: for cancerous pleural and abdominal effusion, recombinant human interleukin-2.3 to 1 million IU/m2/time, try to remove the effusion in the cavity and then inject, 1 to 2 times/week, 2 to 4 weeks (or the effusion disappears) as a course of treatment. (2) Local administration to tumor lesions: limited to research and observation by oncologists.

The most common adverse reactions are fever and chills, which are related to the dosage. Generally, it is a transient fever (about 38°C), and there may also be chills and high fever. The body temperature can return to normal 3 to 4 hours after stopping the drug. Some patients may experience nausea, vomiting, and cold-like symptoms. Subcutaneous injections may cause local redness, swelling, nodules, and pain. All side effects can recover on their own after stopping the drug. When used in larger doses, this product may cause capillary leak syndrome, which manifests as hypotension, peripheral edema, temporary renal insufficiency, etc. The safe dosage should be strictly controlled when using this product, and symptomatic treatment can be given if the above reactions occur.

1. Patients with a history of allergy to the ingredients of this product. 2. Patients with high fever, severe heart disease, hypotension, severe heart and kidney insufficiency, abnormal lung function or those who have undergone organ transplantation. 3. Recombinant human interleukin-2, or previous history of toxic reactions related to it: 1. Sustained ventricular tachycardia; 2. Uncontrolled arrhythmia; 3. Chest pain accompanied by electrocardiogram changes, angina pectoris or myocardial infarction; 4. Cardiac tamponade; 5. Renal failure requiring dialysis for 72 hours; 6. Coma or toxic psychosis for 48 hours; 7. Intractable or refractory epilepsy; 8. Intestinal ischemia or perforation; 9. Gastrointestinal bleeding requiring surgery; 10. Pregnant women should use with caution.

Precautions for children: Precautions for pregnancy and lactation: Pregnant women should use with caution. Precautions for the elderly:

Not yet clear.

Keep sealed.

200,000 IU

24 months

Shenyang Sunshine Pharmaceutical Co., Ltd.

• Founded in:

  1993-01-03

• Address:

  No. 3, 1A, No. 10 Road, Shenyang Economic and Technological Development Zone

• Tax NO.:

  9121010660460338X6

• Registered Funds:

  1,000,000,000 Yuan

• Website:

  Log in to view

• Email:

  Log in to view